Lanx Medtech's Wholly-Owned Subsidiary Blue Sail Prosper Completes RMB 900 Million Capital Increase with CEC Capital as Exclusive Financial Advisor

2024Year1Month25DayEvening, Bluesail Medical (002382.SZ）Announcement: The Company’s cardiovascular and cerebrovascular business entity, its wholly-owned subsidiary Beijing Lanfan Baisheng Medical Technology Co., Ltd. (hereinafter referred to as ““Bluesail Baisheng”) intends toIntroduction of Strategic InvestorsCapital Big Health Industry (Beijing) Fund (Limited Partnership), Hebei Linkong Private Equity Fund Management Co., Ltd., and Linqu County High-Tech Industrial Investment Co., Ltd. carried out capital increase and share expansion, investorsTotal cash capital injection into Lanfan Baisheng amounted to RMB 9 100 million yuan。 

CEC CAPITAL served as the exclusive financial advisor to Lanfan Baisheng in this transaction. This deal represents the largest single private equity financing transaction in China’s medical device sector over the past two years.

As the holding platform for Bluesail Medical’s Cardiovascular and Cerebrovascular Business Division, Lanfan Baisheng was established by integrating entities including Singapore’s Biosensors International Group (which includes China’s Jiwei Medical), Germany’s NVT, and the Bluesail Shanghai R&D Center. Building on this foundation, the company has expanded its global footprint, diversified its product portfolio, and strengthened localization efforts in China, assembling an R&D and management team comprising top-tier talent from both domestic and international markets. Its commercialized product offerings span coronary intervention implants, valve replacement and repair systems, and distributed products, including the XinYue series.^®, Broad-Minded^®XinXun™, BioFreedom^®, Allegra™ and other products, among which BioFreedom^®It is the global “gold standard” product in the field of high bleeding risk (HBR) patients.

This capital increase involves diverse forms of ownership, including state-owned and private capital. The strategic investors introduced in this capital increase for Beijing Lanfan Baisheng Medical Technology Co., Ltd. (hereinafter referred to as "Lanfan Baisheng") have, on one hand, optimized Lanfan Baisheng’s equity structure. By leveraging the advantageous resources of industrial funds in the big health sector and state-owned investment platforms, the company has accessed high-quality industrial resources, creating synergies between capital and the industrial chain. On the other hand, considering Lanfan Baisheng’s own development needs and comprehensive capital operation planning, this capital increase helps supplement the funds required for operational growth, accelerates market expansion in the field of high-end innovative medical devices, and aligns with the long-term strategic development goals of both Bluesail Medical and Lanfan Baisheng.

Li Gang, Partner and Co-Head of Healthcare at CEC CAPITALIt stated: “As an exceedingly rare, platform-based medical device enterprise in the high-value consumables sector with deep roots in China and a highly globalized system, Bluesail Baisheng boasts strong performance growth and significant brand influence. We believe the company will seize this opportunity to pool resources from its controlling shareholder, new investors, local governments, and other stakeholders, emerging as a standout and leader among Chinese medical device companies in the new era of global expansion.”"This transaction also marks another milestone deal involving assets of a listed company since CEC CAPITAL implemented its strategic upgrade in 2023, fully pivoting to a new strategy of providing multi-dimensional, in-depth investment banking services to listed companies, large enterprise groups, and multinational corporations. It once again demonstrates CEC CAPITAL’s exceptional institutional capabilities in executing complex transactions such as asset spin-offs, restructuring, mergers and acquisitions integration, and the introduction of industrial and government capital."